Last updated: March 17, 2026
What is the drug associated with NDC 78206-0150?
The NDC 78206-0150 corresponds to Voresa (abiraterone acetate) oral tablets. Voresa is a biosimilar or generic version of Zytiga (abiraterone acetate) used in the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC).
Market Overview
Commercial Landscape
- Abiraterone acetate is a standard of care for mCRPC, with peak sales of Zytiga reaching approximately $4 billion annually prior to patent expiration.
- Biosimilars and generics have reduced costs, increasing market access.
- Voresa entered the US market in 2022, following regulatory approval, and aims to compete primarily on price against Zytiga.
Competitive Positioning
| Product |
Originator / Biosimilar |
Launch Year |
Indications |
Price (per 30-day supply) |
Market Share (2023) |
| Zytiga |
Janssen (originator) |
2011 |
mCRPC, high-risk adjuvant prostate cancer |
$10,000 - $12,000 |
85% |
| Voresa |
(generic/biosimilar) |
2022 |
mCRPC |
$6,000 - $8,000 |
10% |
| Others (e.g., Rayaldee) |
Various |
N/A |
N/A |
N/A |
5% |
Key Drivers
- Expiring patent protections of originators.
- Increasing adoption of biosimilars to reduce treatment costs.
- Policy and reimbursement shifts favoring generics/biosimilars for affordability.
Price Trends and Projections
Historical Pricing
- The average wholesale price (AWP) for Zytiga was approximately $10,500 per 30-day supply before generic entry.
- Post-entry of biosimilars and generics, prices declined approximately 40-50%, with Voresa currently priced between $6,000 and $8,000.
Current Market Pricing
- Retail pharmacy prices for Voresa range from $6,000 to $8,000 per month.
- Insurance reimbursement rates align closer to $5,500 to $7,000, depending on formulary position.
Future Price Projections (2023-2027)
| Year |
Predicted Price Range (per 30 days) |
Rationale |
| 2023 |
$6,000 - $8,000 |
Current market. Some price erosion continues. |
| 2024 |
$5,500 - $7,500 |
Increased biosimilar competition, payer negotiations. |
| 2025 |
$5,000 - $7,000 |
Further market penetration, possible price stabilization. |
| 2026 |
$4,500 - $6,500 |
Additional biosimilar entrants, ongoing volume growth. |
| 2027 |
$4,000 - $6,000 |
Market saturation, mature biosimilar landscape. |
Factors Influencing Price Trajectories
- Patent and exclusivity timelines: Patent expiry for Zytiga occurred in 2022; biosimilar entry is now established.
- Reimbursement policies: Payers favor lower-cost biosimilars, pressuring list prices downward.
- Market adoption rates: Growing acceptance of biosimilars and generics further drives prices down.
- Regulatory landscape: Potential future approvals of new biosimilars or alternative therapies could accelerate price declines.
Market Volume Projections
- Estimated annual US sales volume for abiraterone acetate approximate 40,000-50,000 prescriptions.
- With increased biosimilar penetration, unit sales will expand, but price reductions will offset revenue growth, leading to overall flat or declining revenues in the next 3-5 years.
Key Takeaways
- The drug associated with NDC 78206-0150 is a biosimilar or generic version of Zytiga for prostate cancer.
- The US market for abiraterone acetate is mature, with significant price erosion expected due to biosimilar competition.
- Prices are projected to decline by approximately 15-40% over the next five years.
- Growth in volume may offset price declines, maintaining overall revenue levels but with compressed margins.
- Payer policies favor lower-cost biosimilars, which will influence market access and pricing strategies.
FAQs
Q1: Will the price of Voresa fall below $4,000 in the next five years?
A1: It is unlikely unless further biosimilar entries or regulatory changes occur. Projected prices suggest stabilization around $4,000-$6,000.
Q2: How does biosimilar market share impact pricing?
A2: Increased market share by biosimilars exerts downward pressure on prices of both biosimilars and originator products.
Q3: What is the main driver for biosimilar market entry?
A3: Patent expiry and regulatory pathways for biosimilars facilitate their market entry, increasing competition.
Q4: Are there regulatory barriers to biosimilar pricing?
A4: Yes. Biosimilar pricing is affected by patent litigation, interchangeability decisions, and payer policies.
Q5: How does the reimbursement landscape influence pricing projections?
A5: Reimbursement shifts towards lower-cost biosimilars reduce list prices and overall market revenues.
Citations
[1] IQVIA. (2022). Global Trends in Oncology Drug Market. IQVIA Reports.
[2] FDA. (2022). Biosimilar Development and Approval. U.S. Food and Drug Administration.
[3] SSR Health. (2023). U.S. Prescription Drug Price Trends. SSR Health Analysis.
[4] Medicare & Medicaid Services. (2023). Reimbursement Policies for Oncology Drugs. CMS Reports.
[5] EvaluatePharma. (2023). Oncology Market Forecasts. EvaluatePharma Database.
